I wonder if Dr. Nissen wants to revive the fortunes of Omacor. They stopped the Strength Trial because of the superiority of Vascepa. If Amarin loses the appeal, maybe he sees an opening in the CV field. If a Covid-19 trial of Omacor proves that it works for that indication, that would help their cause. A 13,000 patient trial of Omacor has more chance of a statistical significant finding than Amarin's 200 patient trial in Canada (which is the only one that I am familiar with (although Amarin said that there are several studies being done).
A long-time Amarin poster has no clue about competitors but Judge Du "called out" due to "fish oil" comment … (which was not a mistake … but a lot of posters are biased … Vascepa is fish oil acc. to Amarin - see ITC Complaint - but is not the same as COMMON fish oil).
Amazing how certain people make the leap from "won't work, it's just fish oil" to "of course, we always knew about fish oil". No matter how consistently V uniquely splits arrows on the bull's eye. Too bad V doesn't work on pigheaded cynics.